Minehiko Inomata

ORCID

Publication Activity (10 Years)

Years Active: 2018-2023
Publications (10 Years): 4

Top Venues

Thoracic cancer

Diagnostics (Basel, Switzerland)

Tumori

Pathology oncology research : POR

This page only lists publications with an associated author ORCID identifier.

Publications

Minehiko Inomata, Takeshi Tsuda, Tomomi Ichikawa, Masahiro Matsumoto, Isami Mizushima, Kenji Azechi, Naoki Takata, Nozomu Murayama, Kana Hayashi, Takahiro Hirai, Zenta Seto, Kotaro Tokui, Yasuaki Masaki, Chihiro Taka, Seisuke Okazawa, Kenta Kambara, Shingo Imanishi, Hirokazu Taniguchi, Toshiro Miwa, Ryuji Hayashi, Shoko Matsui, Kazuyuki Tobe
Efficacy of immune checkpoint inhibitor therapy in patients with pulmonary sarcomatoid carcinoma in clinical practice. Thoracic cancer (2023)
Zenta Seto, Naoki Takata, Nozomu Murayama, Kotaro Tokui, Seisuke Okazawa, Kenta Kambara, Shingo Imanishi, Toshiro Miwa, Ryuji Hayashi, Shoko Matsui, Minehiko Inomata
Irinotecan monotherapy as third- or further-line treatment for patients with small cell lung cancer. Tumori 107 (6) (2020)
Minehiko Inomata, Kenji Azechi, Naoki Takata, Kana Hayashi, Kotaro Tokui, Chihiro Taka, Seisuke Okazawa, Kenta Kambara, Shingo Imanishi, Toshiro Miwa, Ryuji Hayashi, Shoko Matsui, Kazuyuki Tobe
Association of Tumor PD-L1 Expression with the T790M Mutation and Progression-Free Survival in Patients with EGFR-Mutant Non-Small Cell Lung Cancer Receiving EGFR-TKI Therapy. Diagnostics (Basel, Switzerland) 10 (12) (2020)
Minehiko Inomata, Takahiro Hirai, Zenta Seto, Kotaro Tokui, Chihiro Taka, Seisuke Okazawa, Kenta Kambara, Tomomi Ichikawa, Shingo Imanishi, Toru Yamada, Toshiro Miwa, Ryuji Hayashi, Kazuyuki Tobe
Clinical Parameters for Predicting the Survival in Patients with Squamous and Non-squamous-cell NSCLC Receiving PD-1 Inhibitor Therapy. Pathology oncology research : POR 26 (1) (2018)

Minehiko Inomata

Publication Activity (10 Years)

Top Topics

Top Venues